Cel-Sci Corp. (CVM)

May 16, 2025

StockNews.com Begins Coverage on CEL-SCI (NYSE:CVM) - Defense World

May 16, 2025

May 15, 2025

CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results - Yahoo Finance

May 15, 2025

May 14, 2025

Cel-Sci: Fiscal Q2 Earnings Snapshot - Stamford Advocate

May 14, 2025

May 08, 2025

CEL-SCI (NYSE:CVM) Earns Sell Rating from Analysts at StockNews.com - Defense World

May 08, 2025

May 04, 2025

CEL-SCI Co. (NYSE:CVM) Shares Sold by Geode Capital Management LLC - Defense World

May 04, 2025

May 02, 2025

LD Micro 360 Companies --Set to Present this Week. - ACCESS Newswire

May 02, 2025

May 02, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

May 02, 2025

May 02, 2025

Take off with Cel-Sci Corp (CVM): Get ready for trading - Sete News

May 02, 2025

May 02, 2025

Top investors say Ares Management Corp (ARES) ticks everything they need - Sete News

May 02, 2025

May 01, 2025

A stock that deserves closer examination: Cel-Sci Corp (CVM) - uspostnews.com

May 01, 2025

Apr 30, 2025

Investing in Cel-Sci Corp (CVM) Is Getting More Attractive - knoxdaily.com

Apr 30, 2025

Apr 30, 2025

CVM’s Stock Journey: What Investors Need to Know About Cel-Sci Corp’s Performance - investchronicle.com

Apr 30, 2025

Apr 30, 2025

Curbline Properties Corp (CURB) Becoming More Attractive for Investors - knoxdaily.com

Apr 30, 2025

Apr 30, 2025

Metric Analysis: Coca-Cola Femsa S.A.B. DE C.V. ADR (KOF)’s Key Ratios in the Limelight - DWinneX

Apr 30, 2025

Apr 30, 2025

Analyzing Ratios: Cel-Sci Corp (CVM)’s Financial Story Unveiled - DWinneX

Apr 30, 2025

Apr 30, 2025

Ratios Revealed: Decoding Applied Dna Sciences Inc (APDN)’s Financial Health - DWinneX

Apr 30, 2025

Apr 30, 2025

CEL-SCI (NYSE:CVM) Coverage Initiated by Analysts at StockNews.com - Defense World

Apr 30, 2025

Apr 25, 2025

Cel-Sci Corp [AMEX: CVM] Sees Increase in Stock Value - knoxdaily.com

Apr 25, 2025

Apr 25, 2025

US biotech seeks Saudi approval for cancer treatment - Arabian Gulf Business Insight | AGBI

Apr 25, 2025

Apr 23, 2025

CEL-SCI to seek Saudi approval for cancer treatment - Investing.com

Apr 23, 2025

Apr 23, 2025

CEL-SCI Corp To File For Regulatory Approval Of Multikine In Saudi Arabia - marketscreener.com

Apr 23, 2025

Apr 23, 2025

CEL-SCI's Cancer Drug Eyes Breakthrough Status in Saudi Arabia as MENA Cancer Cases Set to Double - Stock Titan

Apr 23, 2025

Apr 23, 2025

Market Momentum Report: Cel-Sci Corp (CVM)’s Positive Close at 0.27 - DWinneX

Apr 23, 2025

Apr 23, 2025

Its Stock Has Paid Off Big Time For Cel-Sci Corp - Sete News

Apr 23, 2025

Apr 23, 2025

CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market - Yahoo Finance

Apr 23, 2025

Apr 22, 2025

An Analysis of Cel-Sci Corp (CVM)’s Potential Price Growth - knoxdaily.com

Apr 22, 2025

Apr 22, 2025

Parsons Corp [PSN] Investment Appeal on the Rise - knoxdaily.com

Apr 22, 2025

Apr 22, 2025

Cel-Sci Corp (CVM) presents a great opportunity, but the stock is slightly overvalued - uspostnews.com

Apr 22, 2025

Apr 22, 2025

StockNews.com Initiates Coverage on CEL-SCI (NYSE:CVM) - Defense World

Apr 22, 2025

Apr 14, 2025

12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga

Apr 14, 2025

Apr 12, 2025

CEL-SCI's Multikine (CVM) Shows Promising Survival Rates in Head and Neck Cancer Study - GuruFocus

Apr 12, 2025

Apr 11, 2025

12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga

Apr 11, 2025

Apr 09, 2025

CVM stock touches 52-week low at $0.18 amid sharp annual decline - Investing.com Australia

Apr 09, 2025

Apr 09, 2025

CVM stock touches 52-week low at $0.18 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 09, 2025

Apr 08, 2025

Breakthrough Cancer Study: New Data Shows 306% Survival Boost for Multikine Treatment - Stock Titan

Apr 08, 2025

Apr 08, 2025

New Study in the Scientific Journal "Cancer Cell" Supports CEL-SCI’s Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses - Yahoo Finance

Apr 08, 2025

Apr 06, 2025

CEL-SCI (NYSE:CVM) Now Covered by StockNews.com - Defense World

Apr 06, 2025

Apr 05, 2025

Top Companies in Radiation Therapy Devices (Apr, 2025) - Tracxn

Apr 05, 2025

Mar 31, 2025

CVM stock touches 52-week low at $0.23 amid sharp annual decline By Investing.com - Investing.com South Africa

Mar 31, 2025

Mar 31, 2025

CVM stock touches 52-week low at $0.23 amid sharp annual decline - Investing.com Australia

Mar 31, 2025

Mar 31, 2025

Cel-Sci Corp’s Market Journey: Closing Weak at 0.24, Down -0.08 - DWinneX

Mar 31, 2025

Mar 24, 2025

Breakthrough: New Cancer Drug Delivers 95% Quality of Life Improvement for Head & Neck Patients - Stock Titan

Mar 24, 2025

Mar 24, 2025

CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients - Yahoo Finance

Mar 24, 2025

Mar 21, 2025

CVM stock touches 52-week low at $0.26 amid sharp annual decline - Investing.com Australia

Mar 21, 2025

Mar 21, 2025

CVM stock touches 52-week low at $0.26 amid sharp annual decline By Investing.com - Investing.com South Africa

Mar 21, 2025

Mar 21, 2025

Cel-Sci Corp (CVM) Volatility Hits 12.01%: What Good Investors Need To Be Aware Of - Stocks Register

Mar 21, 2025

Mar 18, 2025

CEL-SCI announces closing of $2.5 million offering -March 18, 2025 at 05:23 pm EDT - Marketscreener.com

Mar 18, 2025

Mar 18, 2025

CEL-SCI Secures $2.5M Funding: Major Push for FDA-Designated Cancer Immunotherapy - StockTitan

Mar 18, 2025

Mar 18, 2025

Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 18, 2025